Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 12, Issue 1, 2009, Pages 79-85

  Naik, Runa S ^a   Hartmann, Joachim ^a   Kiewert, Cornelia ^a   Duysen, Ellen G ^b   Lockridge, Oksana ^b   Klein, Jochen ^a,c  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; CHOLINESTERASE; DONEPEZIL; RIVASTIGMINE; CARBAMIC ACID DERIVATIVE; CHOLINESTERASE INHIBITOR; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

ACETYLCHOLINE BRAIN LEVEL; ACETYLCHOLINESTERASE DEFICIENCY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME DEFICIENCY; FEMALE; HIPPOCAMPUS; IN VIVO STUDY; MALE; MICRODIALYSIS; MOUSE; NONHUMAN; WILD TYPE; ANIMAL; BRAIN; METABOLISM; MOUSE MUTANT;

ACETYLCHOLINE; ACETYLCHOLINESTERASE; ANIMALS; BRAIN; CHOLINESTERASE INHIBITORS; FEMALE; HIPPOCAMPUS; INDANS; MALE; MICE; MICE, KNOCKOUT; MICRODIALYSIS; PHENYLCARBAMATES; PIPERIDINES;

EID: 70349319533     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/J3MK59     Document Type: Article

References (33)

1. Gold PE. Acetylcholine: cognitive and brain functions. Neurobiol Learn Mem 2003; 80: 194-210.
2. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999; 66: 137-147.
3. McKeith IG, Mintzer J, Aarsland A, The International Psychogeriatric Association Expert Meeting on DLB. Dementia with Lewy bodies. Lancet Neurol 2004; 3: 19-28.
4. Tiraboschi P, Hansen L, Alford M, Merdes A, Masliah E, Thal LJ, Corey-Bloom J. Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease. Arch Gen Psychiatry 2002; 59: 946-951.
5. Soreq H, Seidman S. Acetylcholinesterase-new roles for an old actor. Nature Rev Neurosci 2001; 2: 294-302.
6. Giacobini E, Zhu XD, Williams E, Sherman KA. The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex. Neuropharmacology 1996; 35: 205-211.
7. Ohara T, Tanaka K, Fukaya H, Demura N, Iimura A, Seno N. SDZ ENA 713 facilitates central cholinergic function and ameliorates spatial memory impairment in rats. Behav Brain Res 1997; 83: 229-233.
8. Gauthier S. Advances in the pharmacotherapy of Alzheimer's disease. CMAJ 2002; 166: 616-623.
9. Aarsland D, Mosimann UP, McKeith IG. Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2004; 17: 164-171.
10. Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. Nature Rev Neurosci 2003; 4: 131-138.
11. Darvesh S, Hopkins DA. Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus. J Comp Neurol 2003; 463: 25-43.
12. Giacobini E. Cholinesterases: new roles in brain function and in Alzheimeŕs disease. Neurochem Res 2003; 28: 515-522.
13. Ballard CG, Greig NH, Guillozet-Bongaarts AL, Enz A, Darvesh S. Cholinesterases: roles in the brain during health and disease. Curr Alzheimer Res 2005; 2: 307-318.
14. Xie W, Stribley JA, Chatonnet A, Wilder PJ, Rizzino A, McComb RD, Taylor P, Hinrichs SH, Lockridge O. Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetylcholinesterase. J Pharmacol Exp Ther 2000; 293: 896-902.
15. Mesulam MM, Guillozet A, Shaw P, Levey A, Duysen EG, Lockridge O. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 2002; 110: 627-639.
16. Greig NH, Utsuki T, Ingram DK, Wang Y, Pepeu G, Scali C, Yu Q-S, Mamczarz J, Holloway HW, Giordano T, Chen D, Furukawa K, Sambamuri K, Brossi A, Lahiri DK. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc Natl Acad Sci USA 2005; 102: 17213-17218.
17. Perry EK, Perry RH, Blessed G, Tomlinson BE. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 1978; 4: 273-277.
18. Arendt T, Bruckner MK, Lange M, Bigl V. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development--a study of molecular forms. Neurochem Int 1992; 21: 381-396.
19. Giacobini E. Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol Res 2004; 50: 433-440.
20. Duysen EG, Stribley JA, Fry DL, Hinrichs SH, Lockridge O. Rescue of the acetylcholinesterase knockout mouse by feeding a liquid diet; phenotype of the adult acetylcholinesterase deficient mouse. Brain Res Dev Brain Res 2002; 137: 43-54.
21. Li B, Stribley JA, Ticu A, Xie W, Schopfer LM, Hammond P, Brimijoin S, Hinrichs SH, Lockridge O. Abundant tissue butyrylcholinesterase and its possible function in the acetylcholinesterase knockout mouse. J Neurochem 2000; 75: 1320-1331.
22. Hartmann J, Kiewert C, Duysen EG, Lockridge O, Greig NH, Klein J. Excessive hippocampal acetylcholine levels in acetylcholinesterasedeficient mice are moderated by butyrylcholinesterase activity. J Neurochem 2007; 100: 1421-1429.
23. Hartmann J, Kiewert C, Duysen EG, Lockridge O, Klein J. Choline availability and acetylcholine synthesis in the hippocampus of acetylcholinesterase-deficient mice. Neurochem Int 2008; 52: 972-978.
24. Dutar P, Bassant M-H, Senut M-C, Lamour Y. The septohippocampal pathway: structure and function of a central cholinergic system. Physiol Rev 1995; 75: 393-427.
25. Kosasa T, Kuriya Y, Matsue K, Yamanishi Y. Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats. Eur J Pharmacol 1999; 380: 101-107.
26. Scali C, Casamenti F, Bellucci A, Costagli C, Schmidt B, Pepeu G. Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats. J Neural Transm 2002; 109, 1067-1080.
27. Bar-on P, Millard CB, Harel M, Dvir H, Enz A, Sussman JL, Silman I. Kinetics and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine. Biochemistry 2002; 41: 3555-3564.
28. Groner E, Ashani Y, Schorer-Apelbaum D, Sterling J, Herzig Y, Weinstock M. The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates. Mol Pharmacol 2007; 71: 1610-1617.
29. Kawashima K, Sato A, Yoshizawa M, Fujii T, Fujimoto K, Suzuki T. Effects of the centrally acting cholinesterase inhibitors tetrahydroaminoacridine and E2020 on the basal concentration of extracellular acetylcholine in the hippocampus of freely moving rats. Naunyn-Schmiedeberǵs Arch Pharmacol 1994; 350: 523-528.
30. Liston DR, Nielsen JA, Villalobos A, Chapin D, Jones SB, Hubbard ST, Shalaby IA, Ramirez A, Nason D, White WF. Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimeŕs disease. Eur J Pharmacol 2004; 486: 9-17.
31. Tasker A, Perry EK, Ballard CG. Butyrylcholinesterase: impact on symptoms and progression of cognitive impairment. Expert Rev Neurother 2005; 5: 101-106.
32. Gauthier S, Emre M, Farlow MR, Bullock R, Grossberg GT, Potkin SG. Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors. Curr Med Res Opin 2003; 19: 707-714.
33. Figiel GS, Sadowsky CH, Strigas J, Koumaras B, Meng X, Gunay I. Safety and efficacy of rivastigmine in patients with Alzheimeŕs disease not responding adequately to donepezil: an open-label study. Primary Care Companion J Clin Psychiatry 2008; 10: 291-298.